Search Bar & Filters
Found 6 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the efficacy and safety of iza-bren, a bi-specific antibody-drug conjugate targeting EGFR and HER3 with a chemotherapy payload, compared to treatment chosen by physicians including paclitaxel, nab-paclitaxel, carboplatin plus gemcitabine, and capecitabine for patients with first-line metastatic triple-negative breast cancer TNBC or low estrogen receptor ER-low, HER2-negative breast cancer who cannot receive anti-PDL1 or endocrine therapies. This study includes adults with locally advanced, recurrent inoperable, or metastatic disease who meet specific eligibility criteria. Participants are randomly assigned to receive iza-bren or one of the physicians choice chemotherapy regimens. The treatments are given at specified doses on scheduled days. The study includes two phases Phase 2 to determine the recommended dose of iza-bren and Phase 3 to compare progression-free survival and other outcomes. The study will last several years, with follow-up extending up to approximately 47 months after randomization. During the study, participants will undergo regular assessments including imaging scans to measure tumor response, laboratory tests, and monitoring for adverse events. Quality of life questionnaires will also be completed. Researchers will track progression-free survival, overall survival, treatment-related side effects, tumor size changes, and patient-reported outcomes to evaluate the treatments. The total participation duration may extend up to several years depending on treatment response and follow-up requirements.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of KarXT combined with KarX-EC in treating cognitive impairment in people with mild to moderate Alzheimers Disease. This phase 3 study is randomized, double-blind, and placebo-controlled, aiming to improve thinking abilities measured by specific standardized assessments. Participants will receive either KarXT plus KarX-EC or a placebo at specified doses on designated days. The study lasts 24 weeks, during which outcomes like changes in cognitive function, daily living activities, and behavioral symptoms will be assessed. The trial includes an active comparison group and a placebo group to evaluate treatment effects. Throughout the study, participants and their caregivers will attend regular visits for clinical assessments, including cognitive tests ADAS-Cog11, caregiver interviews, and monitoring of adverse events and vital signs. Researchers will carefully track safety and treatment response over the 24-week period to understand the impact of the study drugs on Alzheimers symptoms.
Actively Recruiting
Researchers are studying whether the medicine nerandomilast can help slow lung changes in people aged 40 or older who have a family history of pulmonary fibrosis. This condition causes scarring in the lungs, making breathing difficult, and early lung changes detected by scans may lead to this scarring. The study aims to find ways to prevent lung fibrosis from getting worse in those at higher risk due to family history. Participants are randomly assigned to two groups one takes nerandomilast tablets and the other takes placebo tablets that look the same but contain no medicine. They take one tablet twice daily for about 2 to 3 years. The chance of receiving nerandomilast is 3 in 5. The study includes frequent visits during the first 2 years, approximately every 3 months, then visits every 6 months in the third year, along with phone calls every 3 months during that last year. During the study, doctors regularly check lung function and perform chest scans to monitor lung changes and see if nerandomilast affects the condition. They also track participants health and any side effects. The main measure is the time until lung changes worsen over the full trial period. The total participation time is about 2 to 3 years with ongoing assessments throughout.
Actively Recruiting
Researchers are evaluating whether compressive cryotherapy can reduce opioid use and improve recovery after primary total knee arthroplasty in patients with knee osteoarthritis. This randomized controlled trial compares compressive cryotherapy using the Game Readyae device with standard care using traditional ice packs to assess effects on postoperative pain and recovery. Participants will be randomly assigned to receive either compressive cryotherapy with the Game Readyae device or standard cryotherapy with ice packs. The Game Readyae device delivers circulating cold water combined with intermittent pneumatic compression applied to the knee for 20 minutes, four times daily during the first 7 days after surgery. Compression starts on day 3 at medium pressure. The standard care group will apply ice packs as needed and elevate the limb. Both groups follow the same postoperative pain relief and rehabilitation plan. During the 7-day postoperative period, participants will record daily pain levels using a visual analog scale and document opioid use in a pain diary. On day 7, researchers will evaluate knee swelling, hematoma size, and quality of recovery using the QoR-15 questionnaire. The main outcome measured is total opioid consumption during the first 7 days after surgery. This study lasts for the first week post-surgery, with follow-up assessments at day 7.
Actively Recruiting
Researchers are creating a registry of patients with Pulmonary Hypertension who receive medical care at the Hospital Italiano of Buenos Aires. The study includes both new cases of pulmonary hypertension type I and existing patients diagnosed before the registry began, following updated diagnostic guidelines. This registry aims to gather important data on this condition to better understand its occurrence and outcomes. This is an observational study without treatment interventions. It enrolls patients diagnosed with Pulmonary Arterial Hypertension PAH WHO group 1 based on specific hemodynamic criteria from the 2022 ESCERS guidelines. Patients are included prospectively or as prevalent cases within the hospitals health maintenance organization. Participants will be monitored to collect data on the prevalence and incidence of pulmonary hypertension over one year. Researchers will also track mortality rates within that timeframe. The study involves reviewing medical records and clinical information. Participation continues as long as the patient remains in care, with the registry ongoing since 2017 and expected to continue through 2031.
Actively Recruiting
Epithelial ovarian cancer, including fallopian tube and primary peritoneal cancer, is the most deadly gynecologic cancer with a 5-year survival rate of about 50%. This observational study aims to evaluate the agreement in folate receptor alpha FRa immunohistochemistry IHC testing among adult female participants with ovarian cancer. Researchers will use archived tissue samples to assess FRa expression, collecting data from about 1,000 participants. The study involves testing stored tissue biopsies using FRa IHC to measure protein overexpression. These samples are surgical or biopsy specimens collected within the last 5 years containing enough viable tumor cells. The study has no treatment or drug administration, focusing on reviewing archived samples and participants medical charts. Participants are not required to undergo any new procedures or treatments. The research team will review existing clinical data and perform laboratory testing on stored samples. The main outcome is the measurement of FRa overexpression through IHC at local and central sites. The trial duration is about one year, with no added burden or visits for participants.